Verity & Verity LLC Trims Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Verity & Verity LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 20.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,790 shares of the company’s stock after selling 700 shares during the period. Verity & Verity LLC’s holdings in Novo Nordisk A/S were worth $332,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVO. International Assets Investment Management LLC boosted its holdings in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd bought a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $98,765,000. Price T Rowe Associates Inc. MD lifted its holdings in Novo Nordisk A/S by 10.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after buying an additional 823,036 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after buying an additional 689,441 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Performance

NVO opened at $99.82 on Tuesday. The firm has a market cap of $447.95 billion, a PE ratio of 32.30, a P/E/G ratio of 1.31 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $117.94 and a 200-day simple moving average of $129.42. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.